CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback